Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL4995021 | 0.93 | NOS2 (0.32) | TLR2NOS2NOS3NOS1 | |
| Proline SCHEMBL140698 | 0.87 | TLR2 (0.34) | TLR2NOS2NOS3NOS1DPP4 | |
| SCHEMBL3100834 | 0.86 | TLR2 (0.30) | TLR2 | |
| Proline SCHEMBL12813264 | 0.86 | TLR2 (0.31) | TLR2DPP4 | |
| Glutamic Acid SCHEMBL16934712 | 0.84 | GRM8 (0.35) | — | |
| Proline SCHEMBL3519298 | 0.83 | TLR2 (0.32) | TLR2NOS2NOS3NOS1DPP4 | |
| SCHEMBL2043828 | 0.82 | NOS2 (0.37) | TLR2NOS2NOS3NOS1DPP4 | |
| Proline SCHEMBL8582773 | 0.82 | TLR2 (0.34) | TLR2NOS2NOS3NOS1PRCP | |
| Lysine SCHEMBL15942522 | 0.81 | GSR (0.47) | TLR2DPP4DPP8DPP9DPP7 | |
| Aspartic Acid SCHEMBL5692189 | 0.80 | GRIK1 (0.37) | NOS2NOS3NOS1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876578-B | Amphiphilic glucan derivative carrier targeting tumor-associated fibroblasts, and preparation and application of pharmaceutical composition of amphiphilic glucan derivative carrier | 中国药科大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-112876578-A | Amphiphilic glucan derivative carrier targeting tumor-associated fibroblasts, and preparation and application of pharmaceutical composition of amphiphilic glucan derivative carrier | 中国药科大学 | 2021-06-01 | — | — | CN | disclosed |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1943257-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | GENENTECH, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276435-A1 | Fibroblast activation protein inhibitor compounds and methods | FAP, FIBP, FGFR1 | TLR2 4306/4885NOS2 4245/4885NOS3 4120/4885 |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | FAP, FIBP, FGFR1 | TLR2 4306/4885NOS2 4245/4885NOS3 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.